CRF antagonists DuPont

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 274-279

  Preti, A ^a  

^a Genneruxi Medical Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 BROMO 4 (1 METHYLETHYL)PHENYL] 7 [BIS(2 METHOXYETHYL)AMINO] 5 METHYL [1,2,3]TRIAZOLO [4,5 D]PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; CHLORDIAZEPOXIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DMP 904; IL 488; INDOLE DERIVATIVE; JE 884; POLYAZAINDOLE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; SA 627; SD 491; SV 030; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; XQ 771;

ANXIETY NEUROSIS; BLOOD BRAIN BARRIER; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; NONHUMAN; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; CYCLOPROPANES; HUMANS; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035113465     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia
2. Novel imidazolo and triazolopyrimidine derivatives as corticotropin-releasing hormone (CRH) receptor antagonists
3. Anilinopyrimidines as corticotropin releasing hormone (CRH) antagonists
4. Corticotropin-releasing factor receptor antagonists
5. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines
6. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin
7. Neuroendocrinology and pathophysiology of the stress system
8. A role for CRH and the sympathetic nervous system in stress-induced immunosuppression
9. Steroid effects on central neurons and implications for psychiatric and neurological disorders
10. Corticotropin releasing hormone in the pathophysiology of melancolic and atypical depression and in the mechanism of antidepressant drugs
11. Corticotropin-releasing hormone and inflammation
12. The concepts of stress and stress system disorders
13. Elevated concentrations of CSF corticotrophin-releasing factor-like immunoreactivity in depressed patients
14. Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims
15. Neuroscience of addiction
16. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary
17. Localization of novel corticotropin releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 mRNA expression
18. Physiological and behavioral responses to corticotrophin-releasing factor administration: Is CRF a mediator of anxiety of stress response?
19. Physiology and pharmacology of corticotrophin-releasing factor
20. Neuropeptides and human sleep
21. The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimi dine: A corticotropin-releasing factor (hCRF1) antagonist
22. American Chemical Society 219th National Meeting (Part VIII) Division of Medicinal Chemistry, San Francisco, CA, USA
23. Retro-purines: Nonpeptide corticotropin-releasing factor receptor ligands
24. 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyraz olo[1,5-a]-1,3,5-triazine: A potent, orally bioavailable CRF1 receptor antagonist
25. Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
26. Corticotropin-releasing factor1 receptor as a target for therapeutic intervention
27. Corticotropin-releasing factor antagonists: Therapeutic potential in the treatment of affective disorders
28. Imidazo[4,5-b] and imidazo[4,5-c]pyridines as corticotropin releasing factor ligands
29. Nonpeptide CRF antagonists: Hydroxy- and alkoxy-alkyl pyrimidines and triazines
30. Retro-purine CRF antagonists: SAR refinement of the aryl and side chain groups
31. CRF1 antagonists via Suzuki and Negishi couplings of 3-pyridyl boronic acids or bromides with chloronitropyridines
32. Pyrazolo-[1,5-a]-1,3,5-triazine CRF receptor antagonists: Synthesis and structure-activity relationships of 8-heteroaryl analogs
33. Pyrazolo-[1,5-a]-1,3,5-triazine CRF receptor antagonists: Synthesis and structure-activity relationships of 8-(substituted phenyl) analogs
34. Corticotrophin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischaemia or activation of NMDA receptors in the rat brain
35. NBI-30775
36. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates
37. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated
38. The role of corticotropin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats
39. Cortisol levels during human aging predict hippocampal atrophy and memory deficits